Findings to be presented at the 2019 American Society of Clinical
Oncology’s Genitourinary Cancers Symposium
SAN FRANCISCO & CULVER CITY, Calif.--(BUSINESS WIRE)--
Scientific teams from NantHealth
(NASDAQ:
NH) and NantOmics
will present two posters at the American Society of Clinical Oncology’s
(ASCO) Genitourinary Cancers Symposium this week. The two companies,
respective leaders in molecular profiling research and genomic testing
solutions, teamed together to explore the significance of RNA expression
and individual biomarkers in determining why some patients do not
respond to targeted cancer therapies based on DNA genomic profiling
alone.
The first poster session will provide insights on individual biomarkers
obtained from liquid biopsies that may potentially improve immune
checkpoint therapies for prostate cancer. The second session will
feature research, conducted with experts from the UC San Diego Health
Moores Cancer Center, that demonstrates the benefits of examining
discrepancies between DNA alterations and RNA expression that could be
the cause of treatment failure for people with metastatic kidney,
bladder, and prostate cancer.
“While next generation sequencing for advanced cancers has become
routine, not all patients are responding to targeted treatments based
solely on DNA genomic profiling,” said Sandeep “Bobby” Reddy, MD, Chief
Medical Officer, NantHealth. “It is becoming clear that we must delve
deeper into RNA expression, as well as identify key biomarkers, to
develop effective cancer treatments and therapies.”
NantHealth and NantOmics will present the following posters at this
year’s Genitourinary Cancers Symposium:
-
Concomitant characterization of androgen receptor (AC) and immune
checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with
metastatic castration resistant prostate cancer (mCRPC) –
11:30AM-1:00PM & 5:30PM-6:30PM, 2/14/2019, Session A, Board M21,
Abstract #286
-
RNA sequencing in addition to next generation sequencing in
advanced genitourinary cancers reveals transcriptomic silencing of DNA
mutations: Implications for resistance to targeted therapeutics – 7:00AM-7:55AM
& 12:30PM-2:00PM, 2/16/2019, Session C, Board E22, Abstract #583
The 2019 Genitourinary (GU) Cancers Symposium is a three-day scientific
and educational meeting in San Francisco designed to meet the needs of
physicians and other members of the cancer care and research community
who diagnose, treat, and study GU malignancies.
About NantHealth
NantHealth, a member of the NantWorks ecosystem of companies, provides
leading solutions across the continuum of care for patients, physicians,
payors and biopharmaceutical organizations to enable cutting edge data
and technology focused on fulfilling the goal to empower clinical
decision support and improved patient outcomes. NantHealth’s GPS Cancer®
molecular profiling provides comprehensive DNA, RNA, tumor-normal
analysis combined with pharmacogenomics data. Liquid GPS®
provides a non-invasive testing of cfDNA and cfRNA to monitor and
potentially select targeted therapy, chemotherapy, and immunotherapy.
NantHealth’s Precision Insights® Portal is the only solution
available to blend guidelines-based regimen information powered by the
Eviti® evidence-based platform with personalized insights
from GPS Cancer® and Liquid GPS® to provide
oncologists an integrated view of treatment options informed by both
standard of care and patient-specific molecular insights. For more
information, please visit www.nanthealth.com.
About NantOmics:
NantOmics, a member of the NantWorks ecosystem of companies, invented
and developed the technologies that drive NantHealth’s GPS Cancer®
platform. GPS Cancer® provides actionable intelligence and
molecularly driven decision support for cancer patients and their
providers at the point of care. NantOmics is the first molecular
analysis company to pioneer an integrated approach to unearthing
molecular variances and profiles that initiate and drive cancer, by
analyzing both normal and tumor cells from the same patient and
following identified variances from DNA to RNA to protein to drug.
Having pioneered tumor-normal DNA sequencing and introduced whole RNA
transcriptomic analysis to better inform clinical treatment decisions,
NantOmics has provided molecular insights for thousands of cancer
patients.
NantOmics has a highly scalable cloud-based infrastructure capable of
storing and processing thousands of genomes a day, computing genomic
variances in near real-time and correlating proteomic pathway analysis
with quantitative gene expression and pharmacogenomic signatures, which
guides the use of immunotherapies, chemotherapies and targeted
therapies. Clinical studies for neoepitope vaccines using NantOmics’
proprietary technologies and novel artificial intelligence platforms are
currently underway. For more information please visit www.nantomics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190214005310/en/
Jen Hodson
NANT
jhodson@nantworks.com
Source: NantHealth